Feasibility Study of Switching to Nilotinib After First-line Imatinib in the Chronic Phase of Chronic Myeloid Leukemia

First-line imatinib can achieve efficacy similar to that with first-line nilotinib after standardized management in accordance with the European Leukemia Network recommendations. Treatment with imatinib as first-line treatment, with a switch to nilotinib after standardized management is feasible and effective. Both nilotinib and imatinib have been shown to be well tolerated and safe.

Source: Clinical Lymphoma, Myeloma and Leukemia - December 8, 2019 Category: Hematology Authors: Yilin Chen, Hua Yin, Lifeng Chen, Yingyuan Xiong, Li Meng, Jingming Guo, Haiyan Wang, Weiming Li Tags: Original Study Source Type: research